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Background: The provision of appropriate medical and nursing care for people with dementia is a major challenge
for the healthcare system in Germany. New models of healthcare provision need to be developed, tested and
implemented on the population level. Trials in which collaborative care for dementia in the primary care setting
were studied have demonstrated its effectiveness. These studies have been conducted in different healthcare
systems, however, so it is unclear whether these results extend to the specific context of the German healthcare
system.
The objective of this population-based intervention trial in the primary care setting is to test the efficacy and
efficiency of implementing a subsidiary support system on a population level for persons with dementia who live at
home.
Methods and study design: The study was designed to assemble a general physician-based epidemiological
cohort of people above the age of 70 who live at home (DelpHi cohort). These people are screened for eligibility to
participate in a trial of dementia care management (DelpHi trial). The trial is a cluster-randomised, controlled
intervention trial with two arms (intervention and control) designed to test the efficacy and efficiency of
implementing a subsidiary support system for persons with dementia who live at home. This subsidiary support
system is initiated and coordinated by a dementia care manager: a nurse with dementia-specific qualifications who
delivers the intervention according to a systematic, detailed protocol. The primary outcome is quality of life and
healthcare for patients with dementia and their caregivers. This is a multidimensional outcome with a focus on four
dimensions: (1) quality of life, (2) caregiver burden, (3) behavioural and psychological symptoms of dementia and
(4) pharmacotherapy with an antidementia drug and prevention or suspension of potentially inappropriate
medication. Secondary outcomes include the assessment of dementia syndromes, activities of daily living, social
support health status, utilisation of health care resources and medication.
Discussion: The results will provide evidence for specific needs in ambulatory care for persons with dementia and
will show effective ways to meet those needs. Qualification requirements will be evaluated, and the results will help
to modify existing guidelines and treatment paths.
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The provision of appropriate medical and nursing care
for people with dementia is a major challenge for the
healthcare system in Germany. As a result of demo-
graphic changes, the overall population will decrease
over the next few decades and there will be an increase
in the number of people above the age of 65 [1]. These
changes will be accompanied by an increase of people
with age-associated illnesses such as diabetes, hyperten-
sion and dementia. The global prevalence of dementia in
this age group was estimated to be as high as 24 million
in 2001, and, according to current estimates, it is pre-
dicted to double every 20 years and affect more than 80
million people worldwide by 2040. The estimated annual
incidence and prevalence of Alzheimer disease, the most
frequent cause of dementia in the elderly, dramatically
rise concomitantly with age. Incidence rates from ap-
proximately 0.4% in people ages 65 to 69 up to nearly
10% in people over 90 years of age have been reported,
along with a prevalence from approximately 2% in
people ages 65 to 69 years up to more than 25% in those
over 90 years of age [2]. In Germany, this estimate cor-
responds to a prevalence of approximately 1.1 million
people and an annual incidence of 250,000 new patients
[3]. Analyses and prognoses for the federal state of
Mecklenburg-Western Pomerania reveal that the num-
ber of people with dementia will increase from about
80% in 2005 to approximately 91% in 2030 [4]. To meet
the challenges associated with these trends, new models
of healthcare provision need to be developed, tested and
implemented on the population level.
A current review describes the status of dementia re-
search and care in Germany [5]. According to that re-
view, there is an urgent need for population-based
research to meet the challenges of (1) early identification
in the sense of widespread availability of early diagnostic
testing, including the proven effectiveness and early ini-
tiation of therapy where appropriate; (2) multimorbidity,
with dementia’s interfering with the treatment of other
diseases, as well as comorbidity that aggravates the clin-
ical course of dementia; (3) integration of multiprofes-
sional strategies to develop comprehensive treatment
and management of persons with dementia in the exist-
ing healthcare system; and (4) consequently addressing
caregiver burden. The epidemiology of healthcare re-
search has provided valuable results to support ways to
address each of these needs separately. However,
population-based research targeting this complex situ-
ation in a comprehensive, integrated way still needs to
be carried out.
It is well-known that the population-based efficacy of
early intervention is dependent on the effectiveness of
the intervention itself, the availability of the intervention
for all people affected and the utilisation of theintervention by these people [6]. Current data show,
however, that many persons with dementia are not diag-
nosed at all or are diagnosed only at a later, already clin-
ically advanced stage of the disease. In a German
population-based study of persons with dementia, 51%
of participants had received the diagnosis “dementia”
from their general practitioners (GPs) (unpublished data,
JR Thyrian). Dementia was overrepresented in depressed
patients and in those with hearing impairments and
restricted mobility. Persons living in single-person
households, however, were often underdiagnosed with
dementia [7]. The risks and benefits of systematic
screening for cognitive impairment have been discussed
with much controversy in the international literature,
and no data exist about systematic screening for the pur-
pose of dementia intervention in Germany [8-11].
Multimorbidity is a challenge unmet in Germany. Sub-
jects with dementia frequently have other age-associated
illnesses. In a Swedish population-based study, investiga-
tors found that only 34% of all persons with dementia
did not have comorbid diseases. Additionally, dementia
is a risk factor for other diseases. The probability for a
concomitant diagnosis of depression was discovered to
be raised by a factor of 1.9 in persons with dementia, the
probability of coronary heart disease by a factor of 3.1
and the probability of fractures by a factor of 3.1 [12].
Persons with Alzheimer disease were found to have an
increased risk of acute illnesses (pneumonia), falls and
hospitalisations in the United States [13] and in Ger-
many [14]. A current study of primary care practices in
Germany has yielded increased odds ratios for stroke
(2.04) and depressive symptoms (1.36) in cognitively
impaired persons [15]. Therefore, to deliver adequate
treatment and care of persons with dementia, appropri-
ate treatment of blood pressure, diabetes and a large
array of other chronic diseases is of utmost importance.
This already implies that treatment and care for people
with dementia usually require multiprofessional
approaches.
There are already many professions involved in the
provision of adequate, guideline-oriented, high-quality
care to persons with dementia. GPs typically know their
patients for a long time and have developed a good rela-
tionship with them, which facilitates treatment. Specialists
such as psychiatrists, neurologists and neuropsychologists
deliver high-quality diagnoses as well as specific advice
regarding, for example, pharmacological treatment. In the
course of the illness, qualified nursing care becomes more
important. In Germany, there is considerable heterogen-
eity in ambulatory services at inpatient and outpatient fa-
cilities that take care of persons with dementia. Different
therapeutic approaches aim to maintain or even increase
everyday functioning and mobility. Self-help groups for
caregivers and caregiver counselling are another important
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home. Even though this enumeration is not complete, it
clearly indicates the complexity of the healthcare system
for persons with dementia and their caregivers in Ger-
many. Few of them, however, have ever been studied with
regard to effectiveness.
Accessibility and utilisation of most of these options,
however, is very much dependent on individual, systemic
and regional variables. There is considerable need for
better integration of care for patients with dementia.
The psychiatric health care system in Germany includes
all aspects of prevention, treatment, rehabilitation, care
and research as well as education, but these areas have
evolved rather separately, so that presently systematic
coordination is lacking. This makes appropriate care for
people with dementia even more difficult. [16] An ad-
equate coordinated management of dementia care is ur-
gently needed.
Relatives very often carry the highest burden of care
for individuals with dementia who live at home. The ex-
istence of a caregiver at home is a prerequisite for good
home-based care, at least when the patient is in the later
stages of dementia. This role is usually taken by spouses
or children [17,18]. A systematic review of health conse-
quences for the caregiver showed that providing care to
relatives with dementia is correlated with negative health
outcomes for the caregiver, which often lead to an earlier
institutionalisation of the person with dementia [19].
This relation is dependent on the age and sex of the
caregiver, the relation to the person with dementia and
other individual variables regarding the caregiver, includ-
ing culture, coping strategies and other personal charac-
teristics [19]. A recent Cochrane review indicated that
there is scientific evidence for the efficacy of programs
to reduce caregiver burden [20]. However, this conclu-
sion was based on very few high-quality intervention
studies. Therefore, population-based studies need to spe-
cifically consider the caregivers as much as the dementia
patients themselves. More comprehensive, integrative,
multiprofessional approaches may have the potential to
improve the health of the caregiver as well as the person
with dementia and to generate economic benefits within
the healthcare system [21,22].
Collaborative care in dementia
Trials in which researchers have studied collaborative
care for dementia patients in the primary care setting
have demonstrated its effectiveness [23-25]. However,
these studies have been conducted outside Germany in
different healthcare systems, so it is unclear whether
these results extend to the specific context of the Ger-
man healthcare system.
A GP-based, cluster-randomised trial for the improve-
ment of healthcare provided for people with dementiaand their caregivers in primary care Germany [26,27]
was effective in improving referral rates to specialists.
Part of the intervention was the recommendation of
support groups and family counselling. The recommen-
dation has increased the utilisation of support groups
and counselling five- and fourfold, respectively. Utilisa-
tion of other support services remained low (less than
10%), with the exception of home nursing and institu-
tional short-term nursing. However, we expect that ac-
tively managing care will have a greater effect on the
healthcare of persons with dementia and their
caregivers.
Objective
The objective of this population-based intervention trial
in the primary care setting is to test the efficacy and effi-
ciency of implementing a subsidiary support system on a
population level for persons with dementia who live at
home. This subsidiary support system is initiated and
coordinated by a dementia care manager (DCM): a nurse
with dementia-specific qualifications. The main goals of
this support system are (1) to improve quality of life, (2)
to reduce caregiver burden, (3) to reduce behavioural
and psychological symptoms of dementia and (4) to op-
timise pharmacotherapy with an antidementia drug and
prevent the prescription of potentially inappropriate
medication (PIM).
Methods and study design
The DelpHi cohort
The DelpHi Study has been designed to assemble a GP-
based epidemiological cohort of people older than
70 years of age who live at home (the DelpHi cohort),
from among whom we will identify those eligible to par-
ticipate in a trial of dementia care management (the Del-
pHi Trial). (see the flowchart of the Delphi Study in
Figure 1.) Participants in the DelpHi Trial will be fol-
lowed prospectively and will be asked to participate in
other trials in the future. Participants will be recruited
from GP-based practices only; no other facilities will be
used to identify eligible persons. All persons identified
by a participating GP to be eligible for the study will be
screened for cognitive impairment. People who meet the
inclusion criteria will be informed in detail about the
DelpHi Trial by the GP and will be asked for their par-
ticipation. All persons who provide their written
informed consent to participate will then be included in
the DelpHi Trial.
This protocol describes the methodology for identify-
ing and recruiting participants for both the cohort study
and the trial parts of the DelpHi Study and the design
and intervention of the DelpHi Trial.
The trial has been designed as a GP-based, rando-
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Figure 1 Flowchart of the DelpHi Trial.
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ping 24-month intervention period and an annual
follow-up assessment. The study design is illustrated in
Figure 2.
Identifying participants
GP practices participating in the DelpHi Study will sys-
tematically screen patients ages 70 years and older in
their routine care. In cases where the screening instru-
ment indicates dementia, the persons are eligible for the
DelpHi Trial and will be informed in detail about the
trial and invited to participate in it. Participants will be
asked to name a caregiver who will be asked to partici-
pate in the trial as well. As cognitive decline is a core
feature of dementia, the GP must evaluate the ability of
the patient to provide his or her informed consent. If the
screened person is not able to give informed consent,the caregiver will be asked to do so. This procedure has
been discussed in detail and has been approved by the
Ethical Committee of the Chamber of Physicians of
Mecklenburg-Western Pomerania (registry number BB
20/11).
The DelpHi trial
Participants and their caregivers will be cluster-
randomised into one of two groups: (1) a DCM group
(DCM, intervention group) or (2) a care-as-usual group
(control group). GP practices represent the clusters for
randomisation. All participants will be contacted by
study staff to arrange a baseline assessment at the per-
sons’ homes.
Participants randomised to the intervention arm will
be contacted by a DCM to arrange the first home visit
during the initial part of the study. Over a period of
GP-practice recruitment 
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Figure 2 Design of the DelpHi Trial.
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with the participant; depending on the individual partici-
pant’s needs, more frequent contacts might be needed
within the first 6 months of the trial.
Participants randomised into the control group will re-
ceive no specific intervention. These participants will be
visited at home for a comprehensive baseline assessment
but will receive care as usual (care-as-usual group).
Because persons with dementia are supposed to bene-
fit from this trial, special emphasis will be put on defin-
ing and classifying participants on the basis of their
dementia syndrome. Because a screening test at the GP
practice is not sufficient and will yield false-positive
results, a comprehensive assessment of all participants
in the control and intervention groups will be
conducted.
Trial intervention
Intervention group: role of dementia care manager
Participants randomised to the intervention group will
receive improved integrative and collaborative care in-
volving different professions where needed. Their care
will be coordinated by a DCM who is specifically trained
in dementia care management. Their GP will receive
comprehensive reports and be closely involved in the
participant’s care. A more detailed description of the
concept of a DCM, including qualifications and imple-
mentation, has been given elsewhere [28].
The DCM, in close cooperation with the GP, will es-
tablish and maintain a comprehensive subsidiary support
system for persons with dementia and their caregivers.
The overall goal of the intervention is to optimise access
to and provision of healthcare for people with dementiaand their caregivers. The DelpHi intervention is com-
plex, multidimensional and multimodal and will be indi-
vidually tailored to each participant and his or her
ambient and social contexts and resources. The starting
point is a detailed and systematic notebook-style,
computer-assisted assessment conducted by the DCM of
the needs of the person with dementia and the caregiver.
Predefined algorithms suggest specific actions and
treatment.
The intervention can be conceptualised as standing on
three pillars: (1) treatment and care management, (2)
medication management and (3) caregiver support. In
improving the person’s situation, the DCM will system-
atically assess the resources and needs in eight action
fields: medical diagnostics and treatment, nursing care
and treatment, nonmedical therapies, social inclusion
and/or support, legal counselling, technical assistance
and telemedicine, pharmacological treatment and care,
and caregiver support and education.
The intervention will be delivered according to a
detailed protocol. The DCM will meet the person with
dementia and the person’s caregiver for the baseline as-
sessment and upon the first interventional visit, usually
at the participant’s home. Further mandatory personal
contacts will then be scheduled monthly for the first
6 months of the intervention and by telephone for the
last 6 months of the intervention period. In addition to
these mandatory contacts, optional contacts will be pos-
sible during the first 6 months. Optional contacts can be
made in person or by telephone, depending on the per-
son’s individual needs and preferences.
The personal resource and needs assessment will be
analysed by the DCM, and a summary will be forwarded
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will be discussed and implemented in close cooperation
with the GP.
Control group
Participants cluster-randomised to the control group will
receive care as usual in a primary care setting.
Inclusion and exclusion criteria
Eligible participants will be identified from among the
patients of the participating GP practices. The inclusion
criteria are that the person must be at least 70 years of
age, living at home, have screened positive for dementia
(score 8 or lower) on the DemTect Scale [29,30] and
meet none of the exclusion criteria. The exclusion cri-
teria are insufficient German-language competence and
other medical conditions that do not allow testing (for
example, hearing impairment, visual impairment).
Sample size calculation
The estimated enrolment for the study is 1,000 partici-
pants and their respective caregivers. This sample size is
necessary in the context of a complex intervention
which could not be proven efficacious in smaller
cohorts. To detect small effects (Cohen’s d= 0.2) in com-
parisons between intervention and control conditions at
a significance level of α= 0.05 and a statistical power of
80%, a sample size of n= 310 persons per group would
be needed. With the longitudinal design we calculate
with a “loss due to follow-up” of 35%, we end up with
n= 477 persons per group with complete data sets.
According to the classification of Cohen, this would
yield enough statistical power to detect small effects
[31].
The required sample size can decrease during the
course of the study if effects on the primary outcomes
should be detected that are, on average, larger than
anticipated in this calculation or if the loss during
follow-up is smaller. If the average effects of this com-
plex intervention on any relevant variable should be
smaller, however, the sample size required to statistically
significantly demonstrate them would be larger.
For example, an efficacy study for the implementation
of a collaborative care model for older adults with Alz-
heimer disease in primary care [25], the primary out-
come, behavioural symptoms measured with the
Neuropsychiatric Inventory (NPI) [32], yielded small to
medium effect sizes between Cohen’s d= 0.4 and
Cohen’s d= 0.68 (our own calculations based on [32]).
For several reasons, however, it is questionable whether
these results are generalisable to Germany. First, the
quality of health care in Germany is different from that
in the United States. The cited study was conducted
with an underserved population, whereas the DelpHiTrial will be conducted with people who benefit from a
high-quality healthcare system. This difference will de-
crease the anticipated effect size. Second, the study itself
will increase healthcare above the level of usual care in
the control group because of the comprehensive assess-
ment at home and in the GP practice. We can control
for these factors; however, they will decrease effect sizes,
and therefore we calculated our sample size for the con-
servative assumption of achieving a small effect.
The sample size will decrease over time for various
reasons. Loss to follow-up due to death, migration, insti-
tutionalisation and decline to consent to participate will
occur. Migration is unlikely to have any larger effect, be-
cause the persons older than 70 years of age tend to be
geographically stable. When a participant is lost to
follow-up, efforts will be made to locate and recontact
the participant. The data will be included in the main
analysis. Decline of initial consent will be documented
whenever possible, together with the reasons provided.
Mortality and institutionalisation will be captured by
regular visits to the GP and in the course of the follow-
up visits at home.
Recruitment
Recruitment will take place in the GP practice on the
basis of the inclusion and exclusion criteria listed above.
Participating GPs will systematically screen their patients
at regular GP visits. Inclusion criteria for GP practices
are that they provide primary care in a residential prac-
tice in Mecklenburg-Western Pomerania. A list of eli-
gible practices is provided by the chamber of physicians
of Mecklenburg-Western Pomerania. Eligible GP prac-
tices are contacted by sending an information letter
about the study and a personal visit by study staff to in-
form GPs face-to-face about the study and all associated
procedures. Upon providing their written consent to
participate in the study, the GP practices are randomly
assigned to either the intervention or control group. Po-
tential participants with dementia who meet the inclu-
sion criteria will be identified by the GP.
If the screening test is positive, the GP will provide
written and oral information about the study to the per-
son with suspected dementia. Because the caregiver is
an equally important target of the study, too, the person
with dementia will be asked to provide contact details of
his or her caregiver, who then is also informed about the
study, usually by the GP. Providing a caregiver is not an
inclusion criterion for the study and can be denied by
the person with dementia. Nevertheless, it is our goal to
recruit caregivers for a large proportion of the persons
with suspected dementia. Because cognitive decline is a
symptom of dementia, the GP has to assess whether the
person with dementia is capable of giving valid written
informed consent. In cases in which the person is
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sent is obtained from the caregiver. The GP collects the
written informed consent forms of the person with de-
mentia and the caregiver. The forms are regularly
retrieved from the GP practice by study staff. Anon-
ymised information regarding the result of the screening
test and the patient’s age and sex is collected from parti-
cipants who decline to participate in the trial to allow
for some basic comparisons between them and the parti-
cipants in the study. The GP receives an incentive of 10€
per screening and 100€ per written informed consent.
As part of the baseline assessment, the study team will
assess the syndrome of dementia by conducting a struc-
tured interview for the diagnosis of dementia according
to the International Classification of Diseases, 10th Revi-
sion, or ICD-10 [33]. This will help identify participants
who were screened false-positive. It also helps to define
the participants recruited into the study according to the
different syndromes of dementia. Participants without a
syndrome of dementia (that is, false-positive) will be
included in the follow-up assessment but excluded in
calculating the study outcome.
Randomisation
Participating GP practices that meet inclusion criteria
and provide written informed consent are randomised
into the trial. Simple randomisation with a 1:1 allocation
ratio is carried out by fair coin-tossing right after the
study team has received the written informed consent
form from the GP. Simple randomisation is recom-
mended by the CONSORT group because it “is elegantly
sophisticated in that it is more unpredictable and sur-
passes the bias prevention levels of all other alternatives”
(http://www.consort-statement.org/consort-statement/
further-explanations/box2_randomisation_minimisation/
). However, coin-tossing in itself is not recommended,
but was chosen for several reasons. There is evidence
that simple coin-tossing will lead to problematic sample
sizes in small clinical trials (N< 100) but that it can be
trusted to generate equal numbers in large trials (N =
>200) [34]. It is also well-known that “[p]roper alloca-
tion concealment frequently frustrates clinical inclina-
tions, which annoys those who do the trials.. . . Many
involved with trials will be tempted to decipher assign-
ments, which subverts randomisation” [35] (p. 614). In
our study, GPs will be randomised after they have given
their written informed consent. This will prevent the
possibility that the initial recruitment of GP practices
might be biased by knowledge of the allocation into the
intervention and control groups. Stratified randomisa-
tion would be difficult because of the continuous process
of enrolling GPs during the trial. Block randomisation
would induce problems due to limited information on
the covariates to be controlled for [34].Follow-up
Data will be collected annually throughout the study.
Data will be collected by the GP practices (during the
screening assessment) at baseline at the person’s home
(notebook computer-assisted face-to-face interviews).
After inclusion of a person and based on explicit
informed consent, secondary data from the person’s
medical record will be abstracted at the GP practice at
baseline and will be repeated annually. The same assess-
ment instruments will be used for the intervention and
control groups.
Outcome measures
The primary outcomes in this complex intervention
trial are quality of life and healthcare for patients with
dementia and their caregivers. These are multidimen-
sional outcomes with a focus on four dimensions: (1)
quality of life, (2) caregiver burden, (3) behavioural
and psychological symptoms of dementia and (4)
pharmacotherapy with an antidementia drug and pre-
vention or suspension of PIM. Quality of life will be
measured using the Quality of Life in Alzheimer’s Dis-
ease instrument [36], which consists of 13 items and
includes “assessments of the individual’s relationships
with friends and family, concerns about finances, phys-
ical condition, mood, and an overall assessment of life
quality” [37] (p. 55). To measure caregiver burden, the
Berliner Inventar zur Angehörigenbelastung (BIZA-D)
[38] will be used. BIZA-D is a standardised, theoretic-
ally grounded, psychometrically validated instrument
used to assess burden and stress. It covers physical ex-
haustion, personal restrictions in life, missing social ap-
preciation, personal development and negative
appraisal. It also assesses tasks required in caring for
the person with dementia, in motivating and guiding,
in supporting in care, in emotional support and in
oversight. The Neuropsychiatric Inventory (NPI), devel-
oped by the Alzheimer’s Disease Cooperative Study
investigators [32], is used as a standardised instrument
to assess behavioural and psychological symptoms. The
assessment of pharmacotherapy with antidementia
drugs focuses on the following substances which are
approved by the drug authorities and recommended by
the current guidelines [39,40]: donepezil, galantamine,
rivastigmine and memantine. Additionally, we evaluate
the reduction of PIM according to the PRISCUS cri-
teria [41] as well as the reduction of anticholinergic
drugs [42].
The following are the secondary outcomes:
1. The Structured Interview for the Diagnosis of
Dementia, or SIDAM [33], will serve to identify
screening false-positives as well as to differentiate
different syndromes of dementia.
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Bayer Activities of Daily Living Scale, or B-ADL
[43,44].
3. Social support will be assessed using the Social
Support Questionnaire (F-SozU) [45].
4. Health status will be assessed using several
instruments that measure health-related variables of
the person with dementia, including the GP records,
the SF-12 Health Survey [46], the standardised
assessment for elderly patients in a primary care
setting (STEP) [47], the Brief Symptom Inventory
(BSI) [48] and the Gesundheitsfragebogen für
Patienten (PHQ-D) [49,50].
5. Utilisation of health care resources will be assessed
according to GP and specialist visits, outpatient
treatments, inpatient treatments, hospitalisations,
nursing home admissions, therapeutic appliances
and provision of informal care [51].
6. Medications will be assessed by the DCM, who
will conduct an information technology-supported
standardised home medication review [52] at the
patient’s home with subsequent medication
management by the patient’s local pharmacy
regarding the frequency of drug-related problems,
intake of PIMs, clinically relevant drug-drug
interactions, adherence, adherence to supportive
activities (that is, medication plan, drug dispenser,
support by care service, reduction of the number
of drugs taken and home medication review)
[52].Data analysis
Statistical analysis Logistic regression analysis will be
conducted to compare the intervention and control
groups regarding their respective average scores on the
primary outcome measure. Secondary analyses will be
conducted using linear or logistic regressions, depending
on the outcome under analysis.
A randomisation check will be conducted by compar-
ing the intervention and control groups on various vari-
ables at baseline. In case of any differences, these
variables will be adjusted for in the analysis of the
outcomes.
Descriptive analyses will be conducted to evaluate
the characteristics of the participants at baseline and
follow-up. Response rates will be calculated for each
group at each time point of analysis and compared be-
tween groups. In univariate and bivariate analyses, the
number of missing data will be identified. In multivari-
able analysis, imputations will be based on the group
averages. Appropriate sensitivity analyses will be
conducted.Withdrawal
Participation in the study is voluntary, and withdrawal
can occur at any time. Upon withdrawal, data will be
anonymised. Anonymised data will be retained unless a
person specifically requests that his or her data be phys-
ically deleted.
Economic analysis
In the economic analysis, we will investigate the effi-
ciency of the intervention in comparison to controls
who received usual care. Efficiency will be quantified as
ratios of predefined clinical outcomes to costs. There-
fore, both all relevant outcomes (primary and secondary)
and all direct costs (dementia care management and util-
isation costs) will be captured and documented through-
out the trial. Furthermore, incremental cost-effectiveness
ratios will be calculated from different viewpoints (soci-
ety, payer and patient), and relevant sensitivity analyses
(multiway, scenario-based and probabilistic) will be con-
ducted. During the course of the trial, detailed cost-
monitoring of the direct care management intervention
will be carried out to identify key factors determining
cost-effectiveness that can be used to inform future de-
mentia care.
Ethical issues
Ethical approval for this trial has been obtained from the
Ethical Committee of the Chamber of Physicians of
Mecklenburg-Western Pomerania (registry number BB
20/11).
An ethical issue specific to this study is the capability
of persons with dementia to give informed consent. In
accordance with the Ethical Committee’s recommenda-
tion, we assigned to the screening GP the decision
regarding a person’s capability of providing consent. In-
formation about dementia and assessing the person’s
capability to consent are routine tasks for GPs in pri-
mary care. In cases of incapability, the caregiver will be
asked to provide written informed consent for the par-
ticipation of the person with dementia.
During the course of the study, it is likely that the per-
son with dementia will lose the capability to consent be-
cause of cognitive decline. The study staff will regularly
check with the GP whether written informed consent
needs to be obtained by the caregiver to keep the person
with dementia in the study. This will be done and docu-
mented prior to any follow-up assessment.
Trial management
The principal investigator (WH) will be in charge of the
overall management of the trial. The scientific coordin-
ator (JRT) will be responsible for the coordination of the
trial. A nursing scientist (AD) will be responsible for the
qualification and quality assurance of the DCM. Study
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running the trial. Delivery of the intervention will be
carried out by specially trained and qualified nurses. A
psychiatrist (GB) will be responsible for treatment and
care management (intervention pillar 1). A pharmacist
(TF) will be responsible for medication management
(intervention pillar 2). A psychologist (JRT) will be re-
sponsible for caregiver support (intervention pillar 3).
Members of the study team will convene weekly to en-
sure compliance with the study protocol and to ensure a
high quality of intervention throughout the study.
Data quality
The data collection process will be based on computer-
assisted personal interviews. All data are entered by the
DCM into electronic case-reporting forms. The DCM
will use a Java-based rich-client platform which is run
on a mobile touch-screen tablet PC. MySQL database
software will be used for data storage. The tablet per-
sonal computer connects to the study server through
designated cradles using virtual private network technol-
ogy. The client server automatically stores all data. Spe-
cial encryption procedures ensure state-of-the-art data
safety. The DCM can print predefined standardised
reports for communication with the GP and the partici-
pating pharmacist by using portable printers with Blue-
tooth access.
The DCMs will receive intensive training in data col-
lection. The baseline training takes approximately 40
hours. Every 3 months the DCMs will undergo a re-
fresher module (4 hours) to ensure data quality. The
DCMs are prompted upon entering implausible data.
All processes concerning data assessment, manage-
ment and preparation for analysis will be defined
according to comprehensive standard operation proce-
dures (SOPs). SOPs are updated every 6 months. Cur-
rently, SOPs address the following topics:
1. The conduct of dementia screening in the GP
practice
2. The first contact with the patient
3. The baseline assessment in the patient’s household,
including application of the software
4. Personal hygiene issues
5. The standardised intervention
6. Medication management by the local pharmacist
7. Data management standards
A scientific advisory board composed of members in-
dependent from the trial and the funding organisations
was elected. Members include dementia experts in vari-
ous fields of research (clinical psychiatry, nursing sci-
ence, family medicine, social politics, intervention
research, epidemiology and so on) and meet once yearly.Expected results
We expect to find statistically significant differences be-
tween the intervention and control groups across all pri-
mary outcome measures. Specifically, persons with
dementia and their caregivers in the intervention group
will have a higher quality of life than those in the control
group. There will be less caregiver burden and less be-
havioural and psychological symptoms of dementia in
persons of the intervention group. The medical treat-
ment with antidementia drugs will be more frequent and
treatment with PIMs will be less frequent than in the
control group. These effects will be dependent on vari-
ous variables, including age, marital status, morbidity,
severity of dementia, cognitive status, activities of daily
living at baseline and others.
Adverse events
We do not expect adverse events to occur during our
trial. Treatment and care will be based on current guide-
lines and supervised by and coordinated with the treating
GPs in routine care. There will be no pharmacological
interventions by the study staff. The study staff are spe-
cifically qualified for the tasks associated with the con-
duct of the intervention.
As in other clinical trials, some adverse events are pos-
sible. One aspect concerns psychological symptoms
which may occur as a result of our questions. The DCM
will receive intense training by the psychiatrist to handle
adverse events. An emergency plan is one part of the
baseline SOPs. During home visits, a telephone contact
with the GP as well as with the trial psychiatrist is pos-
sible. In weekly case conferences, experiences in the




We expect the results to be interpreted as supportive
evidence for a positive impact of the tasks of a DCM in
the primary care setting. The results will provide evi-
dence for specific needs in ambulatory care of persons
with dementia and will show effective ways to meet
those needs. Thus the study will yield information
regarding how to better manage current problems in
routine dementia care. Qualification requirements for
DCM will be evaluated. The results of the study will
help to modify existing guidelines and treatments and
develop new ones.
Generalisability
Because of the real-life settings in which the trial will
take place, the results will be readily generalisable to the
primary care setting in Germany. The study area at this
stage is confined to only one federal state. However, the
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of the primary care system in Germany are identical
across all German states. With Mecklenburg-Western
Pomerania being a rural area in an industrialised nation
struck by demographic change and facing dementia care
as one of the upcoming challenges of the near future,
the results will also elucidate implications for regions fa-
cing similar challenges across the world.
Trial status
Enrolment into the study started on 1 January 2012.
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